mph Bangladesh

Molecule Info


Content & Indication(s)

Biphasic insulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin. Biphasic insulin is a mixture of 70% Human Insulin Isophane Suspension and 30% Human Insulin Injection (rDNA origin). It is an intermediate-acting insulin combined with the more rapid onset of action of Regular human insulin. The duration of activity may last up to 24 hours following injection. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Biphasic insulin is dependent on dose, site of injection, blood supply, temperature, and physical activity. Biphasic insulin is a sterile suspension and is for subcutaneous injection only. It should not be used intravenously or intramuscularly.

This product may be available in following composition & strengths:

  • Each ml suspension contains Human Insulin (rDNA) BP 40 IU (equivalent to 1.388 mg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin (NPH).
  • Each ml suspension contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as 30% soluble Insulin (Regular) and 70% Isophane Insulin (NPH).
  • Each ml suspension contains Human Insulin (rDNA) BP 100 IU (equivalent to 3.47 mg) as 50% soluble Insulin (Regular) and 50% Isophane Insulin (NPH).

Adequate insulin dosage permits patients with diabetes to effectively utilize carbohydrates, proteins and fats. Regardless of dose strength, insulin enables carbohydrate metabolism to occur and thus to prevent the production of ketone bodies by the liver. Some patients might develop severe insulin resistance such that daily doses of several hundred units of insulin or more are required.

Regulation of glucose metabolism is the primary activity of insulin. Insulin lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibit lipolysis, proteolysis, and gluconeogenesis, and enhance protein synthesis and conversion of excess glucose into fat.

Administered insulin, including Biphasic human insulin, substitutes for inadequate endogenous insulin secretion and partially corrects the disordered metabolism and inappropriate hyperglycemia of diabetes mellitus, which are caused by either a deficiency or a reduction in the biologic effectiveness of insulin. When administered in appropriate doses at prescribed intervals to patients with diabetes mellitus, Biphasic insulin restores their ability to metabolize carbohydrates, proteins and fats.

As with all insulin preparations, the duration of action of Biphasic insulin is dependent on dose, site of injection, blood supply, temperature, and physical activity. Clinical experience has shown that it frequently has time action characteristics reflecting both prandial and basal activity.

Biphasic insulin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. Furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

How to use

Please carefully read & follow manufacturer's Patient Instruction Leaflet (PIL) for detailed direction of chosen brand. A generalized guideline may be as follows.

Syringe Use
To help avoid contamination and possible infection, follow these instructions exactly. Disposable syringes and needles should be used only once and then discarded by placing the used needle in a puncture-resistant disposable container. Properly dispose of the puncture-resistant container as directed by your healthcare provider.
Preparing the Dose
1. Wash your hands.
2. Carefully shake or rotate the bottle of insulin several times to completely mix the insulin.
3. Inspect the insulin. Biphasic insulin suspension should look uniformly cloudy or milky. Do not use Biphasic insulin if you notice anything unusual in its appearance.
4. If using a new Biphasic insulin bottle, flip off the plastic protective cap, but do not remove the stopper. Wipe the top of the bottle with an alcohol swab.
5. Draw an amount of air into the syringe that is equal to the Biphasic insulin dose. Put the needle through rubber top of the Biphasic insulin bottle and inject the air into the bottle.
6. Turn the Biphasic insulin bottle and syringe upside down. Hold the bottle and syringe firmly in one hand and shake gently.
7. Making sure the tip of the needle is in the Biphasic insulin suspension, withdraw the correct dose of Biphasic insulin into the syringe.
8. Before removing the needle from the Biphasic insulin bottle, check the syringe for air bubbles. If bubbles are present, hold the syringe straight up and tap its side until the bubbles float to the top. Push the bubbles out with the plunger and then withdraw the correct dose.

9. Remove the needle from the bottle and lay the syringe down so that the needle does not touch anything.

Injection Instructions
1. To avoid tissue damage, choose a site for each injection that is at least 1/2 inch from the previous injection site. The usual sites of injection are abdomen, thighs, and arms.
2. Cleanse the skin with alcohol where the injection is to be made.
3. With one hand, stabilize the skin by spreading it or pinching up a large area.
4. Insert the needle as instructed by your doctor.
5. Push the plunger in as far as it will go.
6. Pull the needle out and apply gentle pressure over the injection site for several seconds. Do not rub the area.
7. Place the used needle in a puncture-resistant disposable container and properly dispose of the puncture-resistant container as directed by your healthcare provider

For detail description, please see the manufacturer's Patient Instruction Leaflet.

Do not use Biphasic insulin:
- if the insulin substance (the white material) remains at the bottom of the bottle after mixing or
- if there are clumps in the insulin after mixing, or
- if solid white particles stick to the bottom or wall of the bottle, giving a frosted appearance.
If you see anything unusual in the appearance of Biphasic insulin suspension in your bottle or notice your insulin requirements changing, talk to your doctor.
Not in-use (unopened): Biphasic insulin bottles not in-use should be stored in a refrigerator, but not in the freezer.
In-use (opened): The Biphasic insulin bottle you are currently using can be kept unrefrigerated as long as it is kept as cool as possible [below 86°F (30°C)] away from heat and light.
Do not use Biphasic insulin after the expiration date stamped on the label or if it has been frozen.

Dosage and Administration

Dosage is individualized and determined by the physician in accordance with the needs of the patient.

Usual dose of Biphasic insulin may be affected by changes in diet, activity, or work schedule. 
Other things that may affect Biphasic insulin dose are:
Illness, especially with nausea and vomiting, may cause your insulin requirements to change. Even if you are not eating, you will still require insulin. You and your doctor should establish a sick day plan for you to use in case of illness. When you are sick, test your blood glucose frequently. If instructed by your doctor, test your ketones and report the results to your doctor.
Good control of diabetes is especially important for you and your unborn baby. Pregnancy may make managing your diabetes more difficult. If you are planning to have a baby, are pregnant, or are nursing a baby, talk to your doctor.
Insulin requirements may be increased if you are taking other drugs with bloodglucose-raising activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy. Insulin requirements may be reduced in the presence of drugs that lower blood glucose or affect how your body responds to insulin, such as oral antidiabetic agents, salicylates (for example, aspirin), sulfa antibiotics, alcohol, certain antidepressants and some kidney and blood pressure medicines. Your healthcare provider may be aware of other medications that may affect your diabetes control.

Before you use Biphasic insulin, tell your healthcare provider if you:
- take any other medicines, especially ones commonly called TZDs (thiazolidinediones).
- have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Biphasic insulin.

Exercise may lower your body's need for insulin during and for some time after the physical activity. Exercise may also speed up the effect of an insulin dose, especially if the exercise involves the area of injection site (for example, the leg should not be used for injection just prior to running). Discuss with your doctor how you should adjust your insulin regimen to accommodate exercise.
When traveling across more than 2 time zones, you should talk to your doctor concerning adjustments in your insulin schedule.

The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients without severe insulin resistance lies between 0.5 and 1.0 unit/kg/day. However, in pre-pubertal children it usually varies from 0.7 to 1.0 unit/kg/day, but can be much lower during the period of partial remission. In situations of insulin resistance, e.g., during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetes patients are often lower, e.g., 0.3 to 0.6 units/kg/day.

An injection should be followed by a meal or snack containing carbohydrates within approximately 30 minutes of administration.

This insulin should be administered by subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm. Subcutaneous injection into the abdominal wall ensures a faster absorption than from other injection sites. Injection into a lifted skin fold minimizes the risk of intramuscular injection. Injection sites should be rotated within the same region. As with all insulin, the duration of action will vary according to the dose, injection site, blood flow, temperature, and level of physical activity.

Insulin should only be administered subcutaneously and do not administer intravenously or intramuscularly.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the content and container permit. Never use the product if it has lost its usual color & consistency. Insulin should not be used after the printed expiration date. Careful attention to manufacturers' packaging leaflet is recommended.


Biphasic insulin is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Biphasic insulin or any of its excipients.


Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH, analog, etc.), species, or method of administration may result in the need for a change in dosage. For Biphasic insulin, extreme caution must be observed in the measurement of dosage because inadvertent overdose may result in serious adverse reaction or life-threatening hypoglycemia.

Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including Biphasic insulin, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.


Dosing Confusion/Dosing Errors

Medication errors associated with Biphasic insulin have occurred and resulted in patients experiencing hyperglycemia, hypoglycemia or death. The majority of errors occurred due to errors in dispensing, prescribing or administration. Careful attention to the above details may prevent the errors significantly.

Manufacturer's instructions for use should always be read and followed before use. The patient should be instructed to inform hospital or emergency department staff of the dose of Biphasic insulin prescribed, in the event of a future hospitalization or visit to the Emergency Department.


Hypoglycemia is the most common adverse reaction of all insulin therapies, including Biphasic insulin. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with Biphasic insulin. As with all insulin preparations, the time course of Biphasic insulin action may vary in different individuals or at different times in the same individual and is dependent on dose, site of injection, blood supply, temperature, and physical activity. Adjustment of dosage of any insulin may be necessary if patients change their physical activity or their usual meal plan. Insulin requirements may be altered during illness, emotional disturbances, or other stresses. Concomitant oral antidiabetic treatment may need to be adjusted.

Any patient who requires Biphasic insulin for control of diabetes should be under close observation until appropriate dosage is established. The response will vary among patients. Most patients will require 2 or 3 injections per day. Insulin resistance, in some patients is transitory; after several weeks or months during which high dosage is required, responsiveness to the pharmacologic effect of insulin may be regained and dosage can be reduced. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia. As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may prevent a risk in situations where these abilities are especially important, such as driving or operating other machinery. Severe hypoglycemia may develop 18 to 24 hours after the original injection of Biphasic insulin.

Hyperglycemia, Diabetic Ketoacidosis, and Hyperosmolar Non-Ketotic Syndrome

Hyperglycemia, diabetic ketoacidosis, or hyperosmolar coma may develop if the patient takes less Biphasic insulin than needed to control blood glucose levels. This could be due to increases in insulin demand during illness or infection, neglect of diet, omission or improper administration of prescribed insulin doses or use of drugs that affect glucose metabolism or insulin sensitivity. Early signs of diabetic ketoacidosis include glycosuria and ketonuria. Polydipsia, polyuria, loss of appetite, fatigue, dry skin, abdominal pain, nausea and vomiting and compensatory tachypnea come on gradually, usually over a period of some hours or days, in conjunction with hyperglycemia and ketonemia. Severe sustained hyperglycemia may result in hyperosmolar coma or death.


Insulin stimulates potassium movement into the cells, possibly leading to hypokalemia, that left untreated may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

Hypersensitivity and Allergic Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Biphasic insulin. Localized reactions and generalized myalgias have been reported with the use of metacresol as an injectable excipient.

Renal or Hepatic Impairment

Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment.

Drug Interactions

Some medications may alter insulin requirements and the risk for hypoglycemia and hyperglycemia.

Pregnancy Category (FDA)and use in Specific Population

Pregnancy Category B All pregnancies have background risk of birth defects, miscarriage, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and is decreased with good glucose control. It is important for patients to maintain good control of diabetes before conception and during pregnancy. Special attention should be paid to diet, exercise and insulin regimens. Insulin requirements may decrease during the first trimester, usually increase during the second and third trimesters and rapidly decline after delivery. Careful glucose monitoring is essential in these patients. Female patients should be advised to tell their physician if they intend to become, or if they become pregnant. Studies show that endogenous insulin only crosses the placenta in minimal amounts. While there are no adequate and well-controlled studies in pregnant women, an extensive body of published literature demonstrates the maternal and fetal benefits of insulin treatment in patients with diabetes during pregnancy. Biphasic insulin is a recombinant human insulin that is identical to the endogenous hormone; therefore, reproduction and fertility studies were not performed in animals.

Labor and Delivery

Careful glucose monitoring and management of patients with diabetes during labor and delivery are required.

Nursing Mothers

Endogenous insulin is present in human milk. Insulin orally ingested is degraded in the gastrointestinal tract. In lactating infants, no adverse reactions have been associated with maternal use of insulin. In a study of eight preterm infants between 26 to 30 weeks gestation, enteral administration of Humulin R did not result in hypoglycemia. Good glucose control supports lactation in patients with diabetes. Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.

Pediatric Use

There are no well-controlled studies of use of Biphasic insulin in children.

Adverse Drug Reaction(s)

Hypoglycemia is one of the most frequent adverse events experienced by insulin users.

It can be brought about by:
1. Missing or delaying meals.
2. Taking too much insulin.
3. Exercising or working more than usual.
4. An infection or illness associated with diarrhea or vomiting.
5. A change in the body's need for insulin.
6. Diseases of the adrenal, pituitary, or thyroid gland, or progression of kidney or liver
7. Interactions with certain drugs, such as oral antidiabetic agents, salicylates (for
example, aspirin), sulfa antibiotics, certain antidepressants and some kidney and
blood pressure medicines.
8. Consumption of alcoholic beverages.

Symptoms of mild to moderate hypoglycemia may occur suddenly and can include:              

- sweating - drowsiness - dizziness - sleep disturbances - palpitation - anxiety - tremor - blurred vision - hunger - slurred speech - restlessness - depressed mood - tingling in the hands, feet, lips, or tongue - irritability - lightheadedness - abnormal behavior - inability to concentrate - unsteady movement - headache - personality changes 

Signs of severe hypoglycemia can include:

- disorientation - seizures - unconsciousness - coma - death 

Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as long duration of diabetes, autonomic diabetic neuropathy, use of medications such as beta adrenergic blockers, changing insulin preparations, or intensified control (3 or more insulin injections per day) of diabetes.

Without recognition of early warning symptoms, the patient may not be able to take steps to avoid more serious hypoglycemia. Patients who experience hypoglycemia without early warning symptoms should monitor their blood glucose more frequently, especially prior to activities such as driving. Mild to moderate hypoglycemia may be treated by eating foods or taking drinks that contain sugar. Patients should always carry a quick source of sugar, such as hard candy, non-diet carbohydrate-containing drinks or glucose tablets.

Hypokalemia: See Precautions

Lipodystrophy: Administration of insulin subcutaneously can result in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue).

Allergy: Local Allergy Patients occasionally experience erythema, local edema, and pruritus at the site of injection. This condition usually is self-limiting. In some instances, this condition may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.

Systemic Allergy Less common, but potentially more serious, is generalized allergy to insulin, which may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalized allergy (anaphylaxis) may be life threatening.

Weight gain: Weight gain can occur with some insulin therapies and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.

Peripheral Edema: Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Drug Interactions

The concurrent use of oral anti-hyperglycemic diabetes agents with Biphasic insulin is not recommended since there are limited data to support such use. A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

Drugs that may increase the blood-glucose-lowering effect of Biphasic insulin and susceptibility to hypoglycemia:

- Oral antihyperglycemic diabetes agents, salicylates, sulfa antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake inhibitors [SSRIs]), pramlintide, disopyramide, fibrates, fluoxetine, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, beta-adrenergic blockers, inhibitors of pancreatic function (e.g., octreotide), and alcohol.

Drugs that may reduce the blood-glucose-lowering effect:

- Corticosteroids, isoniazid, certain lipid-lowering drugs (e.g., niacin), estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents, somatropin, atypical antipsychotics, glucagon, protease inhibitors and thyroid replacement therapy.

Drugs that may increase or decrease blood-glucose-lowering effect:

- Beta-adrenergic blockers, clonidine, lithium salts, and alcohol.

- Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

Drugs that may mask the signs of hypoglycemia:

- Beta-adrenergic blockers, clonidine, guanethidine, and reserpine.


Excess insulin may cause hypoglycemia and hypokalemia. Hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy expenditure, or both. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

Brand/Product Info

Total Products : 20                    
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
ANSULIN 30/70 100 Square Pharmaceuticals Ltd. Insulin Human (rDNA) 100 IU/ml SC Injection 10 ml: 415.00 MRP
ANSULIN 30/70 40 Square Pharmaceuticals Ltd. Insulin Human (rDNA) 40 IU/ml SC Injection 10 ml: 195.00 MRP
ANSULIN 30/70 PEN Square Pharmaceuticals Ltd. Insulin Human (rDNA) 100 IU/ml SC Injection 3 ml: 222.00 MRP
ANSULIN 50/50 INJ Square Pharmaceuticals Ltd. Insulin Human (rDNA) 100 IU/ml SC Injection 10 ml: 415.00 MRP
ANSULIN 50/50 PEN Square Pharmaceuticals Ltd. Insulin Human (rDNA) 100 IU/ml SC Injection 3 ml: 222.00 MRP
HUMULIN 30/70 Eli Lilly/International Agencies (Bd.) Ltd. Biphasic premix human insulin (rDNA) 100 IU/ml Injection 4ml & 10ml vial x1's; 3ml cartridge x5's: 316.00 & 666.00; 1957.30 MRP
INSUL 30/70 Popular Pharmaceuticals Ltd. Biphasic premix human insulin (rDNA) 40 IU/ml,100 IU/ml Injection 40 IU: 195.00; 100 IU 10ml vial x1's & 3ml cartridge x5's: 415.00 & 1110.00 MRP
INSUL 50/50 Popular Pharmaceuticals Ltd. Biphasic premix human insulin (rDNA) 100 IU/ml Injection 10ml vial x1's, 3ml cartridge x5's: 415.00 & 1110.00 MRP
INSULET 30/70 Aristopharma Ltd. Biphasic premix human insulin (rDNA) 100 IU/ml Injection 4ml & 10ml vial: 169.70 & 415.00 MRP
INSULET 50/50 Aristopharma Ltd. Biphasic premix human insulin (rDNA) 100 IU/ml S/C Injection 4ml & 10ml vial: 169.70 & 415.00 MRP
INSUMAN Comb 25 Sanofi Biphasic (25% Soluble/75% Isophane) premix human insulin (rDNA) 100 IU/ml Penfill Injection 5ml vial: 281.70 MRP
MAXSULIN 30/70 Incepta Pharmaceuticals Limited Human Insulin (rDNA) BP 40 & 100 IU/ml as 30% Soluble Human Insulin (Regular) + 70% Isophane Human Insulin (NPH) Injection 10ml vial each: 195.00 & 415.00 MRP
MAXSULIN 30/70 Penset Incepta Pharmaceuticals Limited Human Insulin (rDNA) BP 100 IU as 30% Soluble Human Insulin (Regular) + 70% Isophane Human Insulin (NPH) per ml Injection 4's: 888.00 MRP
MAXSULIN 50/50 Incepta Pharmaceuticals Limited Human Insulin (rDNA) BP 100 IU/ml as 50% Soluble Human Insulin (Regular) and 50% Isophane Human Insulin (NPH) Injection 10ml: 415.00 MRP
MAXSULIN 50/50 Penset Incepta Pharmaceuticals Limited Human Insulin (rDNA) BP 100 IU/ml as 50% Soluble Human Insulin (Regular) and 50% Isophane Human Insulin (NPH), Penset Injection 4's: 888.00 MRP
MIXTARD 30 Novo Nordisk Pharma (Private) Ltd. Biphasic (30% Soluble/70% Isophane) premix human insulin (rDNA) 100 IU/ml Injection 10ml vial: 415.00 MRP
MIXTARD 30 HM Penfill Novo Nordisk Pharma (Private) Ltd. Biphasic (30% Soluble/70% Isophane) premix human insulin (rDNA) 100 IU/ml Penfill S/C Injection 3ml cartridge: 1830.00 MRP
MIXTARD 50 HM Penfill Novo Nordisk Pharma (Private) Ltd. Biphasic (50% Soluble/50% Isophane) premix human insulin (rDNA) 100 IU/ml Penfill S/C Injection 3ml cartridge: 1830.00 MRP
NOVOMIX 30 Flexpen Novo Nordisk Pharma (Private) Ltd. Pre-mixed neutral suspension consisting of rapid acting insulin aspart (rys) (30%) and intermediate-acting protamine insulin aspart (rys) (70%), S/C Injection Injection 3ml pre-filled Flexpen: 860.00 MRP
NOVOMIX 30 Penfill Novo Nordisk Pharma (Private) Ltd. Pre-mixed neutral suspension consisting of rapidacting insulin aspart (rys) (30%) and intermediate-acting protamine insulin aspart (rys) (70%) S/C Injection 3ml cartridge x5's: 3850.00 MRP

| See FDA approved Brand Manufacturer's Prescribing Information |Insulin human, Humulin 70/30 |


Simple Breath Test Might Diagnose Heart Failure An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a...
Osteoporosis drug stops Breast cancer growth   News & Events News & Events     HIGHLIGHTS Osteoporosis drug stops growth of breast cancer...
Generic drug safety info loophole FDA plans to close generic drug safety info loophole The US Food and Drug Administration has announced plans to speed up the dissemination of...
Large trials unpublished   News & Events News & Events   HIGHLIGHTS Almost 1 in 3 of large clinical trials unpublished after...
TB activists boo Indian minister News & Events News & Events   HIGHLIGHTS TB activists at world conference boo Indian minister off...
Key bone marrow protein identified News & Events News & Events   HIGHLIGHTS Key bone marrow protein identified as potential new leukemia...